GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHSE:688505) » Definitions » Piotroski F-Score

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Piotroski F-Score : 5 (As of Oct. 31, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SHSE:688505' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 6
Current: 5

During the past 13 years, the highest Piotroski F-Score of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co was 6. The lowest was 1. And the median was 2.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Piotroski F-Score Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 1.00 1.00 6.00 3.00

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 3.00 N/A 5.00 -

Competitive Comparison of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Net Income was 21.454 + 18.736 + 2.347 + 68.126 = ¥110.7 Mil.
Cash Flow from Operations was 0 + 0 + 43.938 + 0 = ¥43.9 Mil.
Revenue was 185.133 + 142.773 + 147.647 + 260.477 = ¥736.0 Mil.
Gross Profit was 171.742 + 127.113 + 136.772 + 241.952 = ¥677.6 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Jun24) was
(3031.013 + 2946.016 + 2876.688 + 2825.346 + 2848.696) / 5 = ¥2905.5518 Mil.
Total Assets at the begining of this year (Jun23) was ¥3,031.0 Mil.
Long-Term Debt & Capital Lease Obligation was ¥9.0 Mil.
Total Current Assets was ¥1,869.6 Mil.
Total Current Liabilities was ¥481.3 Mil.
Net Income was 72.798 + 101.173 + 8.787 + 59.65 = ¥242.4 Mil.

Revenue was 445.006 + 314.894 + 189.148 + 333.68 = ¥1,282.7 Mil.
Gross Profit was 418.078 + 285.904 + 171.802 + 309.449 = ¥1,185.2 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was
(2701.94 + 0 + 2976.007 + 0 + 3031.013) / 5 = ¥2902.98666667 Mil.
Total Assets at the begining of last year (Jun22) was ¥2,701.9 Mil.
Long-Term Debt & Capital Lease Obligation was ¥11.2 Mil.
Total Current Assets was ¥2,043.1 Mil.
Total Current Liabilities was ¥673.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Net Income (TTM) was 110.7. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Cash Flow from Operations (TTM) was 43.9. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=110.663/3031.013
=0.03651024

ROA (Last Year)=Net Income/Total Assets (Jun22)
=242.408/2701.94
=0.08971628

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's return on assets of this year was 0.03651024. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's return on assets of last year was 0.08971628. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Net Income (TTM) was 110.7. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Cash Flow from Operations (TTM) was 43.9. ==> 43.9 <= 110.7 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=8.983/2905.5518
=0.00309167

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=11.186/2902.98666667
=0.00385327

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's gearing of this year was 0.00309167. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's gearing of last year was 0.00385327. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun24)=Total Current Assets/Total Current Liabilities
=1869.607/481.297
=3.88451829

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=2043.131/673.946
=3.03159452

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current ratio of this year was 3.88451829. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current ratio of last year was 3.03159452. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's number of shares in issue this year was 1043. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's number of shares in issue last year was 1184.332. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=677.579/736.03
=0.92058612

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1185.233/1282.728
=0.92399402

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's gross margin of this year was 0.92058612. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's gross margin of last year was 0.92399402. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=736.03/3031.013
=0.24283301

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun22)
=1282.728/2701.94
=0.47474333

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's asset turnover of this year was 0.24283301. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's asset turnover of last year was 0.47474333. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (SHSE:688505) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Executives
Zhang Wen Bo Core technical personnel
Jiang Jian Ping Core technical personnel
Tao Ji Ning Core technical personnel
Shen Yi Jun Core technical personnel
Li Jun senior management
Xue Yan senior management
Wang Luo Chun Supervisors, core technical personnel
Su Yong Directors, senior managers
Zhao Da Jun Directors, senior managers
Yang Xiao Lin senior management
Gan Yi Min Senior management, core technical personnel
Yu Dai Qing Supervisors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Headlines

No Headlines